Share on StockTwits

Osiris Therapeutics (NASDAQ:OSIR) released its earnings data on Thursday. The company reported ($0.04) EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.16 by $0.20, Analyst Ratings reports. The company had revenue of $13.30 million for the quarter, compared to the consensus estimate of $11.00 million.

On a related note, analysts at Zacks upgraded shares of Osiris Therapeutics from a “neutral” rating to an “outperform” rating in a research note on Friday, May 30th. They now have a $19.00 price target on the stock.

Shares of Osiris Therapeutics (NASDAQ:OSIR) traded down 1.57% during mid-day trading on Thursday, hitting $15.06. The stock had a trading volume of 87,571 shares. Osiris Therapeutics has a 52-week low of $10.05 and a 52-week high of $27.40. The stock’s 50-day moving average is $15.21 and its 200-day moving average is $14.99. The company has a market cap of $515.4 million and a price-to-earnings ratio of 11.96.

Osiris Therapeutics, Inc (NASDAQ:OSIR), is a stem cell therapeutic company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.